The Food and Drug Administration has approved Onexton Gel (clindamycin phosphate and benzoyl peroxide 1.2 percent/3.75 percent, Valeant Pharmaceuticals) for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. » Data behind approval
Share »
ADVERTISEMENT
Best practices in the evaluation and management of actinic keratoses Articles, video, tools and CME on current strategies for managing actinic keratoses lesions using a variety of therapeutic approaches based on efficacy, safety and tolerability.
Read More.
A new study has found substantial inaccuracies in physician directories for Medicare Advantage (MA) patients seeking dermatologic services. » Why is this a problem?
Mild to severe acne patients experienced an average 41.8 percent reduction in inflammatory acne counts after 12 weeks of using the Silk’n Blue (Home Skinovations Ltd) at-home device, according to a study published in the June 2014 issue of the Journal of Cosmetics, Dermatological Sciences and Applications. » More on the findings
Like
Tweet
